Pacira BioSciences, Inc. completed its merger with Viatris Inc. on November 17, 2026, following a tender offer where Viatris acquired all outstanding shares for $36.50 per share in cash. As a result of the transaction, Pacira has become a wholly owned subsidiary of Viatris and entered into supplemental indentures to address its outstanding 2.125% Convertible Senior Notes due 2029.
The U.S. Court of Appeals for the Ninth Circuit partially reversed a lower court ruling, determining that Pacira BioSciences owes royalties to the Research Development Foundation (RDF) for EXPAREL manufactured using its 200-liter process. This decision impacts a previous $28.3 million recovery Pacira received and remands the case to the District Court to recalculate interest owed on other portions of the judgment.
Pacira BioSciences reported a significant increase in net income to $28.5 million for Q3 2026, compared to $5.4 million in Q3 2025, despite a slight decrease in total revenues to $176.7 million. The company's financial position remains stable with $1.2 billion in total assets and a reduction in long-term debt to $293.6 million.
Pacira BioSciences provided a status update on its pending acquisition by Viatris Inc., noting that the tender offer for $36.50 per share commenced on October 30, 2026. Due to the pending merger, the company will not release Q3 2026 earnings or hold a conference call, and it has withdrawn its previously issued 2026 financial guidance.